Literature DB >> 36230590

A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas.

Ruimin He1,2, Xiaohua Yang1, Tengxiang Li1, Yaolin He2, Xiaoxue Xie3, Qilei Chen4, Zijian Zhang5,6,7, Tingting Cheng5,7,8.   

Abstract

Data from 758 patients with lung adenocarcinoma were retrospectively collected. All patients had undergone computed tomography imaging and EGFR gene testing. Radiomic features were extracted using the medical imaging tool 3D-Slicer and were combined with the clinical features to build a machine learning prediction model. The high-dimensional feature set was screened for optimal feature subsets using principal component analysis (PCA) and the least absolute shrinkage and selection operator (LASSO). Model prediction of EGFR mutation status in the validation group was evaluated using multiple classifiers. We showed that six clinical features and 622 radiomic features were initially collected. Thirty-one radiomic features with non-zero correlation coefficients were obtained by LASSO regression, and 24 features correlated with label values were obtained by PCA. The shared radiomic features determined by these two methods were selected and combined with the clinical features of the respective patient to form a subset of features related to EGFR mutations. The full dataset was partitioned into training and test sets at a ratio of 7:3 using 10-fold cross-validation. The area under the curve (AUC) of the four classifiers with cross-validations was: (1) K-nearest neighbor (AUCmean = 0.83, Acc = 81%); (2) random forest (AUCmean = 0.91, Acc = 83%); (3) LGBM (AUCmean = 0.94, Acc = 88%); and (4) support vector machine (AUCmean = 0.79, Acc = 83%). In summary, the subset of radiographic and clinical features selected by feature engineering effectively predicted the EGFR mutation status of this NSCLC patient cohort.

Entities:  

Keywords:  epidermal growth factor; lung adenocarcinoma; machine learning; radiomics

Year:  2022        PMID: 36230590      PMCID: PMC9563411          DOI: 10.3390/cancers14194664

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


  35 in total

1.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Qian Li; Alberto L Garcia; Olya Stringfield; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2016-02-16       Impact factor: 4.785

2.  Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases.

Authors:  Kenichi Suda; Tetsuya Mitsudomi; Yasushi Shintani; Jiro Okami; Hiroyuki Ito; Takashi Ohtsuka; Shinichi Toyooka; Takeshi Mori; Shun-Ichi Watanabe; Hisao Asamura; Masayuki Chida; Hiroshi Date; Shunsuke Endo; Takeshi Nagayasu; Ryoichi Nakanishi; Etsuo Miyaoka; Meinoshin Okumura; Ichiro Yoshino
Journal:  Ann Thorac Surg       Date:  2020-06-29       Impact factor: 4.330

3.  Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.

Authors:  Shu Li; Changwei Ding; Hao Zhang; Jiangdian Song; Lei Wu
Journal:  Med Phys       Date:  2019-08-20       Impact factor: 4.071

4.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

5.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

6.  Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.

Authors:  Wei-Shuai Liu; Lu-Jun Zhao; Qing-Song Pang; Zhi-Yong Yuan; Bo Li; Ping Wang
Journal:  Med Oncol       Date:  2013-11-19       Impact factor: 3.064

7.  Benchmarking of mutation diagnostics in clinical lung cancer specimens.

Authors:  Silvia Querings; Janine Altmüller; Sascha Ansén; Thomas Zander; Danila Seidel; Franziska Gabler; Martin Peifer; Eva Markert; Kathryn Stemshorn; Bernd Timmermann; Beate Saal; Stefan Klose; Karen Ernestus; Matthias Scheffler; Walburga Engel-Riedel; Erich Stoelben; Elisabeth Brambilla; Jürgen Wolf; Peter Nürnberg; Roman K Thomas
Journal:  PLoS One       Date:  2011-05-05       Impact factor: 3.240

8.  Convex Representations Using Deep Archetypal Analysis for Predicting Glaucoma.

Authors:  Anshul Thakur; Michael Goldbaum; Siamak Yousefi
Journal:  IEEE J Transl Eng Health Med       Date:  2020-05-28

9.  Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device.

Authors:  Xian-Ying Li; Chao Zhang; Qin-Lu Zhang; Juan-Li Zhu; Qian Liu; Ming-Wei Chen; Xue-Min Yang; Wen-Li Hui; Ya-Li Cui
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

10.  Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images.

Authors:  Chengdi Wang; Xiuyuan Xu; Jun Shao; Kai Zhou; Kefu Zhao; Yanqi He; Jingwei Li; Jixiang Guo; Zhang Yi; Weimin Li
Journal:  J Oncol       Date:  2021-12-31       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.